Delving into the Latest Updates on Regranion LLC with Synapse

Overview

Basic Info

Introduction

Regranion, LLC is a clinical-stage biopharmaceutical company delivering breakthrough solutions for autoimmune skin diseases by targeting hyperinflammation.

Tags

Cardiovascular Diseases

Skin and Musculoskeletal Diseases

Immune System Diseases

Small molecule drug

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1
Synthetic peptide	1

Top 5 Target	Count

HSP90B(Heat shock protein HSP 90-beta)	1

Stents have evolved through three generations, the latest of which are totally bioresorbable to include drugs targeting restenosis, the surface polymer eluting those drugs, and scaffolds on which those drugs are coated. These scaffolds, however, thus far, have been pharmacologically inactive and remain a potential site for delivering a second drug. Therefore, we sought to evaluate the possibility of modifying a bioresorbable polymer so that it can double as a scaffold for both a stent and a drug targeting impaired re-endothelialization and stent thrombosis.

METHODS AND RESULTS:

We successfully modified a standard bioresorbable terpolymer in a way found to be consistent with the covalent incorporation of lovastatin, as seen on NMR, into a backbone comprised of lactide, glycolide, ε-caprolactone, and lovastatin (60 : 15 : 10 : 15 parts by weight), respectively. This was accomplished through a reaction of the four components of the polymer at 100°C for 18 h in the presence of an alcohol initiator and a scandium catalyst. The resulting terpolymer was fabricated into a scaffold using a novel RSF system developed by 3D Biotek.

CONCLUSION:

It preliminarily appears feasible to fabricate a fourth-generation bioresorbable stent that has the potential to deliver two drugs to the site of the procedure-related vessel lumen injury.

1

News (Medical) associated with Regranion LLC

26 Sep 2023

·endpts.com

Pakistan recalls altered dose of Avastin; FDA rejects Botanix gel

Plus, MC2’s new licensing deal with Regranion and AM-Pharma announces a new CEO and workforce cuts. Pakistan is pulling a dose of Avastin from the market due to incidents of damaged vision in diabetic patients who received off-label “altered” or “diluted” versions of the injection. The Drug Regulatory Authority of Pakistan cited Genius Advanced Pharmaceutical Services, saying the issues are likely due to illegal sales of the drug under non-sterile conditions. Roche’s Avastin is approved to treat colorectal and metastatic carcinomas in Pakistan. It’s not authorized for use in diabetic patients or for other ophthalmic conditions. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

License out/inDrug Approval

100 Deals associated with Regranion LLC

Login to view more data

100 Translational Medicine associated with Regranion LLC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

Login to view more data